Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.
Case: A 71-Year Old Woman With High-Risk Ovarian Cancer
Initial presentation
Currently
Treatment and Follow-Up
Shahin Analyzes Benefits of Individualized Dosing With PARP Inhibitors in Advanced Ovarian Cancer
February 10th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Mark S. Shahin, MD, discussed with participants how they use the individualized dose of niraparib and manage adverse events in patients with advanced ovarian cancer.
Read More